Another Heart Drug Fails, Shocking Cardiologists

 

Another Heart Drug Fails, Shocking Cardiologists

**The scientific hypothesis seemed airtight: lower lipoprotein(a), a genetic risk factor for heart disease, and you'd reduce heart attacks. But Novartis's massive Phase 3 trial just proved the biology is far more complicated than anyone expected.**

---

### Introduction: A "Pioneering" Trial Ends in Disappointment

On September 4, 2026, Novartis delivered news that stunned the cardiology world. The company announced that its experimental drug, pelacarsen, had failed to reduce the risk of heart attacks, strokes, and cardiovascular death in a large, multi-year clinical trial . The drug had successfully lowered levels of lipoprotein(a), or Lp(a)—a genetic risk factor linked to heart disease that affects roughly one in five people worldwide—but that biochemical victory did not translate into fewer cardiovascular events .

For doctors who had been eagerly awaiting the results, the announcement was a major letdown. "These are not the results we hoped for," said Dr. Shreeram Aradhye, Novartis's Chief Medical Officer . William Blair analysts estimated that a successful drug could have generated $6 billion in peak annual U.S. sales alone . Citi analyst Geoff Meacham noted the failure "increases uncertainty across the Lp(a) field" but added he "would not declare the mechanism dead" .

The implications of this failure extend far beyond Novartis. Several other major pharmaceutical companies, including Amgen and Eli Lilly, have similar drugs in development. If lowering Lp(a) doesn't work, what does that mean for their programs? The answer is still unclear—but the trial has forced a fundamental rethink of a long-held hypothesis in cardiovascular medicine.

---

### What Is Lp(a) and Why Does It Matter?

Lipoprotein(a)—pronounced "L-P-little-A"—is a fatty, cholesterol-carrying particle found in the blood. Genetic and epidemiological studies have shown a clear link between high Lp(a) levels and an increased risk of heart attacks, strokes, and other cardiovascular problems .

Here's what makes Lp(a) different from the cholesterol most people worry about:

- **It's genetic.** Lp(a) levels are approximately 90% genetically determined and largely unaffected by diet or lifestyle . You can't exercise it away. You can't diet it away.

- **It's common.** Approximately 20% of people worldwide, and nearly one-third of those with premature cardiovascular disease, have elevated Lp(a) .

- **It's undertested.** Physicians don't often test for the protein because there haven't been medications that can help .

- **It's hard to treat.** Existing cholesterol-lowering drugs like statins do not meaningfully reduce Lp(a). Invasive procedures like lipoprotein apheresis are available but are reserved for severe cases .

The scientific case for targeting Lp(a) was built on a convergence of evidence from observational studies and genetic research . The hypothesis was simple and compelling: if high Lp(a) causes heart disease, then lowering it should prevent heart disease.

Pelacarsen was the first drug to test this hypothesis in a large, definitive trial.

---

### The Failure: What the Pelacarsen Trial Showed

The Lp(a)HORIZON trial was massive and rigorous. It enrolled **8,323 patients** with elevated Lp(a) levels and established cardiovascular disease . Patients received either pelacarsen or a placebo on top of their existing guideline-directed therapies, including statins and blood pressure medications . The trial ran for more than six years .

The primary endpoint was a composite of major adverse cardiovascular events (MACE): cardiovascular death, non-fatal heart attack, non-fatal stroke, and urgent coronary revascularization requiring hospitalization .

**The result?** Pelacarsen did not significantly reduce the risk of MACE compared to placebo . The drug did successfully lower Lp(a) levels "substantially," consistent with previous studies—but that reduction didn't translate into fewer heart attacks or strokes .

"The findings did not demonstrate that this translated into reduced cardiovascular risk in the overall study population," Novartis's Dr. Aradhye stated .

The trial was considered the vanguard of a new era in cardiovascular prevention, and its failure has raised fundamental questions about the entire approach.

---

### Why Didn't It Work?

The failure has sparked intense speculation among cardiologists. Several theories are being debated:

**Theory 1: Deeper Lp(a) Reduction Is Needed**

Pelacarsen lowered Lp(a) levels by roughly 72% on average . But new competing drugs from Amgen and Eli Lilly can lower Lp(a) by more than 95% . It's possible that pelacarsen didn't lower Lp(a) enough to meaningfully affect cardiovascular risk .

"There may be opportunity to consider deeper Lp(a) inhibition than pelacarsen," wrote William Blair analysts . Citi analysts agreed, noting that "[g]reater target suppression could matter if cardiovascular benefit requires crossing a biological threshold" .

**Theory 2: The Trial Was Too Hard to Win**

Modern cholesterol drugs, including high-dose statins and GLP-1 weight-loss drugs, are already so effective at keeping patients healthy that it's become much harder for new experimental drugs to prove they can offer any extra protection . The patients in the Lp(a)HORIZON trial were already receiving excellent standard care, making it difficult to demonstrate an additional benefit .

**Theory 3: Lp(a) May Be a Marker, Not a Cause**

The most unsettling possibility is that Lp(a) is a risk marker, not a root cause. While genetic evidence had strongly suggested a causal role, the trial's failure raises questions about whether lowering Lp(a) alone is sufficient to reduce cardiovascular events .

---

### What Happens Now?

**The full data from the Lp(a)HORIZON trial has not yet been released.** Novartis plans to present the complete results at an upcoming medical meeting, and experts will be combing through the details to understand what happened .

Key questions remain unanswered:

- Did any subgroup of patients benefit?

- Was there any correlation between the magnitude of Lp(a) reduction and the risk of events?

- Were there issues with the trial's design or execution?

"We're going to need to see the full dataset to distinguish a near-neutral result from a directional benefit that missed statistical significance," said Citi's Geoff Meacham .

**For other Lp(a) drugs in development:** The field is certainly shaken. Novartis's failure has "lower[ed] confidence across the class" . But experts are not ready to declare the mechanism dead. Doctors say other drugs are still worth testing . Amgen and Eli Lilly are continuing their programs, and researchers at the National Heart, Lung and Blood Institute remain optimistic .

---

### The Human Element: What This Means for Patients

For the approximately 20% of Americans with elevated Lp(a), the news is deeply disappointing. Many patients with a family history of early heart disease had been hoping for a new treatment option. Currently, there are no approved targeted treatments for high Lp(a) .

**But the story isn't over.** As Gissette Reyes-Soffer, an associate professor at Columbia University Irving Medical Center, put it: "I remain optimistic" .

The failure of pelacarsen is a setback, not a final verdict. Other approaches—including deeper Lp(a) reduction and different drug mechanisms—are still being tested. And even without a targeted Lp(a) drug, there is still much that patients can do to reduce their cardiovascular risk: controlling blood pressure, managing cholesterol, maintaining a healthy weight, and not smoking.

---

### Frequently Asked Questions

**Q: What is Lp(a)?**

A: Lipoprotein(a), or Lp(a), is a type of cholesterol-carrying particle in the blood. High levels are a genetic risk factor for heart attacks, strokes, and other cardiovascular problems .

**Q: How common is high Lp(a)?**

A: Approximately 20% of people worldwide have elevated Lp(a) levels .

**Q: What did the Novartis trial show?**

A: The Phase 3 Lp(a)HORIZON trial showed that pelacarsen successfully lowered Lp(a) levels but did not significantly reduce the risk of heart attacks, strokes, or cardiovascular death compared to placebo .

**Q: Why might pelacarsen have failed?**

A: There are several theories: deeper Lp(a) reduction may be needed; the trial was too hard to win given existing effective treatments; or Lp(a) may be a risk marker rather than a direct cause of disease .

**Q: Does this mean other Lp(a) drugs will fail?**

A: Not necessarily. Other drugs in development reduce Lp(a) more deeply and have different mechanisms of action. Experts are waiting to see the full data from the Novartis trial before drawing conclusions .

**Q: Are there any approved treatments for high Lp(a)?**

A: Currently, there are no FDA-approved treatments specifically designed to lower Lp(a) .

---

### Conclusion: A Setback, Not a Verdict

The failure of Novartis's pelacarsen trial is a significant blow to a field that had been filled with hope. The science seemed compelling. The biological hypothesis appeared solid. The need for a new treatment was clear.

But the human body is remarkably complex, and "the evidence that lowering Lp(a) could reduce cardiovascular risk was based on genetic studies, not clinical trials," as one expert noted. The pelacarsen results "complicate the hypothesis."

However, as researchers often say, null results can be as important as positive ones. The data from this trial will help refine scientific understanding and inform the design of future studies. And the search for new ways to protect hearts—whether through Lp(a) reduction or other strategies—will continue.

---

### Disclaimer

**IMPORTANT:** This article is for informational and educational purposes only and does not constitute medical advice. The information contained herein is based on publicly available sources as of September 2026. You should consult with a qualified healthcare provider for guidance on your specific health situation.